Sign in Sign up for free

Last updated: 17 June 2024 at 4:41pm EST

Herbert Conrad Net Worth




The estimated Net Worth of Herbert J Conrad is at least $7.26 Million dollars as of 16 May 2019. Mr. Conrad owns over 25,000 units of Celldex Therapeutics stock worth over $7,202,013 and over the last 15 years he sold CLDX stock worth over $0. In addition, he makes $62,440 as Independent Director at Celldex Therapeutics.

Mr. Conrad CLDX stock SEC Form 4 insiders trading

Herbert has made over 2 trades of the Celldex Therapeutics stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 25,000 units of CLDX stock worth $24,000 on 16 May 2019.

The largest trade he's ever made was buying 100,000 units of Celldex Therapeutics stock on 7 September 2017 worth over $130,000. On average, Herbert trades about 2,660 units every 13 days since 2009. As of 16 May 2019 he still owns at least 172,959 units of Celldex Therapeutics stock.

You can see the complete history of Mr. Conrad stock trades at the bottom of the page.





Herbert Conrad biography

Herbert J. Conrad serves as Independent Director of the Company. Mr. Conrad had been a director of Celldex Research since March 2004. Mr. Conrad was President of the U.S. Pharmaceuticals Division of Hoffmann-La Roche, Inc., a pharmaceutical company, from 1982 until his retirement in 1993. Mr. Conrad currently serves as Chairman of the Board of Matinas BioPharma Holdings, Inc., a publicly held biopharmaceutical company. Mr. Conrad serves as an Advisor to the Seaver Autism Center at Mount Sinai Hospital. In addition to serving on the board of directors of privately held biotechnology companies, Mr. Conrad has served as Chairman of the Board of Directors of Pharmasset, Inc., GenVec, Inc. and Bone Care International, Inc. Mr. Conrad has also served as director of Arbutus Biopharma Corporation and was a director and co-founder of Reliant Pharmaceuticals, Inc. He received B.S. and M.S. degrees from the Brooklyn College of Pharmacy and an honorary Doctorate in Humane Letters from Long Island University.

What is the salary of Herbert Conrad?

As the Independent Director of Celldex Therapeutics, the total compensation of Herbert Conrad at Celldex Therapeutics is $62,440. There are 17 executives at Celldex Therapeutics getting paid more, with Ronald Pepin having the highest compensation of $1,225,030.



How old is Herbert Conrad?

Herbert Conrad is 87, he's been the Independent Director of Celldex Therapeutics since 2008. There are no older and 24 younger executives at Celldex Therapeutics.

What's Herbert Conrad's mailing address?

Herbert's mailing address filed with the SEC is C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON, NJ, 08827.

Insiders trading at Celldex Therapeutics

Over the last 16 years, insiders at Celldex Therapeutics have traded over $19,527,314 worth of Celldex Therapeutics stock and bought 273,450 units worth $1,157,166 . The most active insiders traders include Rajesh B Parekh, Garry Arthur Neil, and Inc Medarex. On average, Celldex Therapeutics executives and independent directors trade stock every 69 days with the average trade being worth of $1,750,671. The most recent stock trade was executed by Samuel Bates Martin on 14 June 2024, trading 20,169 units of CLDX stock currently worth $204,917.



What does Celldex Therapeutics do?

celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. celldex therapeutics (nasdaq: cldx) was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. the company's pipeline is comprised of therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers, including many underserved or completely un-served orphan indications. this has created a leading pipeline in im



What does Celldex Therapeutics's logo look like?

Celldex Therapeutics Inc. logo

Complete history of Mr. Conrad stock trades at Arbutus Biopharma Corp, Celldex Therapeutics, and Matinas Biopharma Inc

Date
#
Company
 Insider
Trans.
Transaction
 Shares Price per share Total value Shares after Source
16 May 2019 MTNB Matinas Biopharma Holdings Inc Herbert J Conrad
Director
 Buy 25,000 $0.96 $24,000
16 May 2019
172,959 ↗
7 Sep 2017 MTNB Matinas Biopharma Holdings Inc Herbert J Conrad
Director
 Buy 100,000 $1.30 $130,000
7 Sep 2017
3,879,600 ↗


Celldex Therapeutics executives and stock owners

Celldex Therapeutics executives and other stock owners filed with the SEC include: